- Preklinische resultaten met de werkzame stof TOTUM-854 op arteriële hypertensie, verkregen door werk uitgevoerd als onderdeel van een academisch partnerschap met het Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) van de Universiteit van Avignon en op het Riom R&D-platform.
- Een eerste internationale wetenschappelijke erkenning voor TOTUM-854 door een groot cardiovasculair congres.
- TOTUM-854 wordt de derde werkzame stof in de VALBIOTIS-pijplijn die in 2021 de klinische ontwikkelingsfase ingaat.
LA ROCHELLE, Frankrijk – (BUSINESS WIRE) – Regelgevend nieuws:
VALBIOTIS (Parijs: ALVAL) (FR0013254851 – ALVAL, in aanmerking komend voor PEA/ SME), een onderzoeks- en ontwikkelingsbedrijf dat zich inzet voor wetenschappelijke innovatie voor het voorkomen en bestrijden van stofwisselingsziekten, kondigt aan dat de preklinische resultaten verkregen met TOTUM-854 voor arteriële hypertensie zijn geselecteerd door de European Society of Hypertension (ESH) en de International Society of Hypertension (ISH).
VALBIOTIS Selected to Present TOTUM-854’s Results on Arterial Hypertension at the Annual Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) in April 2021
- Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Riom R&D platform.
- A first international scientific acknowledgement for TOTUM-854 by a major cardiovascular congress.
- TOTUM-854 to be the third active substance in the VALBIOTIS pipeline to enter the clinical development phase, in 2021.
LA ROCHELLE, France–(BUSINESS WIRE)– Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL, eligible for PEA / SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that the preclinical results obtained with TOTUM-854 for arterial hypertension have been selected by the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH).
These results, achieved through work undertaken as part of the academic partnership between VALBIOTIS and the University of Avignon, as well as at the Riom R&D platform, will be presented during the annual ESH-ISH Joint Meeting, which will be held virtually from 11 to 14 April 2021.
Pascal SIRVENT, member of the Management Board, Head of Discovery, Preclinical and Translational Research Department at VALBIOTIS, states: “We are thrilled about the selection of these results with TOTUM-854 on high blood pressure for the annual meeting of ESH and ISH, two key learned societies for arterial hypertension around the world. This selection recognizes first and foremost our successful partnership on TOTUM-854 with the University of Avignon. For VALBIOTIS, this marks the first international scientific presentation at a congress dedicated to arterial hypertension. It demonstrates the relevance of our R&D approach in this domain. We take this as a very positive sign for the clinical development of TOTUM-854, a promising active substance in the fight against high blood pressure and the risk of cardiovascular diseases.”
Details about the results will be revealed at the annual ESH-ISH meeting, which will be held virtually from 11 to 14 April 2021.
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
For more information about VALBIOTIS, please visit: www.valbiotis.com.
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about VALBIOTIS’ objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company’s website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS’ shares or securities in any country.
VALBIOTIS / CORPORATE COMMUNICATION
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
ACTIFIN / FINANCIAL COMMUNICATION
+33 1 56 88 11 14